Log in
NASDAQ:PGEN

Precigen Stock Forecast, Price & News

$7.49
+0.01 (+0.13 %)
(As of 11/27/2020 12:00 AM ET)
Add
Compare
Today's Range
$7.15
Now: $7.49
$7.97
50-Day Range
$4.10
MA: $5.23
$7.48
52-Week Range
$1.26
Now: $7.49
$7.97
Volume1.39 million shs
Average Volume1.44 million shs
Market Capitalization$1.39 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.76
Precigen, Inc. discovers and develops the next generation of gene and cellular therapies in the United States. It also provides disease-modifying therapeutics; genetically engineered swine for regenerative medicine applications; proprietary methane bioconversion platform that turns natural gas into energy and chemical products; and reproductive and embryo transfer technologies. In addition, the company offers UltraVector platform that incorporates advanced DNA construction technologies and computational models to design and assemble genetic components into complex gene expression programs; mbIL15, a gene that enhances functional characteristics of immune cells; Sleeping Beauty, a non-viral transposon/transposase system; AttSite recombinases, which breaks and rejoins DNA at specific sequences; AdenoVerse technology platform, a library of engineered adenovector serotypes; and L. lactis is a food-grade bacterium. Additionally, it provides RheoSwitch inducible gene switch that provides quantitative dose-proportionate regulation of the amount and timing of target protein expression; kill switches to selectively eliminate cell therapies in vivo; UltraCAR-T platform for the treatment of cancer; AdenoVerse Immunotherapy, a library of proprietary adenovectors for the gene delivery; and ActoBiotics platform, genetically modified bacteria that deliver proteins and peptides at mucosal sites. Precigen, Inc. has collaboration and license agreements with ZIOPHARM Oncology, Inc.; Ares Trading S.A.; Oragenics, Inc.; Intrexon T1D Partners, LLC; Intrexon Energy Partners, LLC; Intrexon Energy Partners II, LLC; Fibrocell Science, Inc.; OvaXon, LLC; S & I Ophthalmic, LLC; Harvest start-up entities; and Surterra Holdings, Inc. The company was formerly known as Intrexon Corporation and changed its name to Precigen, Inc. in January 2020. Precigen, Inc. was founded in 1998 and is based in Germantown, Maryland.
Read More
Precigen logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 4.2Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

2.18 out of 5 stars


Industry, Sector and Symbol

Industry Commercial physical research
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:PGEN
CUSIPN/A
Phone301-556-9900
Employees770

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$90.72 million
Book Value$0.44 per share

Profitability

Net Income$-322,320,000.00
Net Margins-321.21%

Miscellaneous

Market Cap$1.39 billion
Next Earnings Date3/1/2021 (Estimated)
OptionableOptionable
$7.49
+0.01 (+0.13 %)
(As of 11/27/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive PGEN News and Ratings via Email

Sign-up to receive the latest news and ratings for PGEN and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Precigen (NASDAQ:PGEN) Frequently Asked Questions

How has Precigen's stock price been impacted by Coronavirus (COVID-19)?

Precigen's stock was trading at $2.38 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, PGEN shares have increased by 214.7% and is now trading at $7.49.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of Precigen?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Precigen in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Precigen
.

What stocks does MarketBeat like better than Precigen?

Wall Street analysts have given Precigen a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's winning trading ideas this year have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Precigen wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Precigen's next earnings date?

Precigen is scheduled to release its next quarterly earnings announcement on Monday, March 1st 2021.
View our earnings forecast for Precigen
.

How were Precigen's earnings last quarter?

Precigen, Inc. (NASDAQ:PGEN) posted its quarterly earnings data on Monday, November, 9th. The biotechnology company reported ($0.18) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.14) by $0.04. Precigen had a negative net margin of 321.21% and a negative return on equity of 105.68%.
View Precigen's earnings history
.

What price target have analysts set for PGEN?

2 equities research analysts have issued twelve-month price targets for Precigen's stock. Their forecasts range from $8.00 to $13.00. On average, they anticipate Precigen's share price to reach $10.50 in the next year. This suggests a possible upside of 40.2% from the stock's current price.
View analysts' price targets for Precigen
.

Who are some of Precigen's key competitors?

What other stocks do shareholders of Precigen own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Precigen investors own include ZIOPHARM Oncology (ZIOP), Nordic American Tankers (NAT), Hess (HES), The Boeing (BA), OPKO Health (OPK), Celldex Therapeutics (CLDX), TherapeuticsMD (TXMD), Gilead Sciences (GILD), NVIDIA (NVDA) and Bausch Health Companies (BHC).

Who are Precigen's key executives?

Precigen's management team includes the following people:
  • Mr. Randal J. Kirk, Exec. Chairman (Age 67)
  • Dr. Helen Sabzevari MPH, Ph.D., Pres, CEO & Director (Age 58, Pay $515.09k)
  • Mr. Rick L. Sterling, Chief Financial Officer (Age 56, Pay $546.84k)
  • Mr. Donald P. Lehr, Chief Legal Officer & Corp. Sec. (Age 45, Pay $606.73k)
  • Mr. Jeffrey Thomas Perez, Sr. VP of Intellectual Property Affairs (Age 48, Pay $530.49k)
  • Dr. Thomas D. Reed, Founder & Chief Science Officer (Age 54)
  • Mr. Rutul R. Shah, Head of Operations & Portfolio
  • Mr. Steven Harasym, Head of Investor Relations
  • Marie Rossi, VP of Communications
  • Mr. Rob Russell, Head of HR

What is Precigen's stock symbol?

Precigen trades on the NASDAQ under the ticker symbol "PGEN."

Who are Precigen's major shareholders?

Precigen's stock is owned by many different retail and institutional investors. Top institutional investors include Third Security LLC (45.30%), Miller Value Partners LLC (4.08%), BlackRock Inc. (3.91%), State Street Corp (2.10%), Morgan Stanley (0.59%) and AXA S.A. (0.16%). Company insiders that own Precigen stock include Donald P Lehr, Helen Sabzevari, Jeffrey Thomas Perez, Joel D Liffman, Nir Nimrodi, Randal J Kirk, Rick L Sterling, Robert F Walsh III, Thomas Bostick, Thomas D Reed and Trading SA Ares.
View institutional ownership trends for Precigen
.

Which institutional investors are selling Precigen stock?

PGEN stock was sold by a variety of institutional investors in the last quarter, including BlackRock Inc., Miller Value Partners LLC, AXA S.A., CNH Partners LLC, Squarepoint Ops LLC, Wells Fargo & Company MN, Resources Investment Advisors LLC., and SG Americas Securities LLC. Company insiders that have sold Precigen company stock in the last year include Donald P Lehr, Helen Sabzevari, Jeffrey Thomas Perez, Rick L Sterling, and Thomas Bostick.
View insider buying and selling activity for Precigen
.

Which institutional investors are buying Precigen stock?

PGEN stock was purchased by a variety of institutional investors in the last quarter, including State Street Corp, Third Security LLC, Morgan Stanley, GSA Capital Partners LLP, Sanders Morris Harris LLC, Cubist Systematic Strategies LLC, OLD Mission Capital LLC, and DekaBank Deutsche Girozentrale. Company insiders that have bought Precigen stock in the last two years include Randal J Kirk, and Trading SA Ares.
View insider buying and selling activity for Precigen
.

How do I buy shares of Precigen?

Shares of PGEN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Precigen's stock price today?

One share of PGEN stock can currently be purchased for approximately $7.49.

How big of a company is Precigen?

Precigen has a market capitalization of $1.39 billion and generates $90.72 million in revenue each year. The biotechnology company earns $-322,320,000.00 in net income (profit) each year or ($0.88) on an earnings per share basis. Precigen employs 770 workers across the globe.

What is Precigen's official website?

The official website for Precigen is www.precigen.com.

How can I contact Precigen?

Precigen's mailing address is 20374 Seneca Meadows Parkway, Germantown MD, 20876. The biotechnology company can be reached via phone at 301-556-9900 or via email at [email protected]

This page was last updated on 11/28/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.